The European Union’s landmark Joint Clinical Assessment (JCA) for Ipsen’s orphan-designated drug Ojemda (tovorafenib) has been published, marking a significant…
Read More

The European Union’s landmark Joint Clinical Assessment (JCA) for Ipsen’s orphan-designated drug Ojemda (tovorafenib) has been published, marking a significant…
Read More